tiprankstipranks
Trending News
More News >
RUA Life Sciences (GB:RUA)
LSE:RUA
Advertisement

RUA Life Sciences (RUA) AI Stock Analysis

Compare
3 Followers

Top Page

GB:RUA

RUA Life Sciences

(LSE:RUA)

Rating:55Neutral
Price Target:
RUA Life Sciences has a challenging financial performance with ongoing profitability and cash flow issues despite revenue growth. The technical analysis indicates bearish trends, and the valuation suggests overvaluation. However, positive corporate events, including strategic expansion and leadership confidence, provide potential for future growth, balancing some of the financial and technical risks.

RUA Life Sciences (RUA) vs. iShares MSCI United Kingdom ETF (EWC)

RUA Life Sciences Business Overview & Revenue Model

Company DescriptionRUA Life Sciences (RUA) is a medical technology company focused on the design, development, and manufacturing of innovative medical devices and materials. Operating primarily in the healthcare and life sciences sectors, RUA specializes in products that utilize advanced polymer technologies to enhance medical procedures and improve patient outcomes. The company's core offerings include biocompatible polymers used in vascular grafts, soft tissue patches, and other implantable medical devices.
How the Company Makes MoneyRUA Life Sciences generates revenue through the sale of its proprietary medical devices and materials, which are primarily based on their unique biocompatible polymer technologies. The company partners with healthcare providers, medical device manufacturers, and distributors to reach end-users such as hospitals and clinics. Revenue streams include direct sales of products, licensing agreements for their proprietary technology, and collaborative partnerships that may involve co-development or manufacturing agreements. The company's earnings are influenced by its ability to innovate and maintain strong relationships within the medical device supply chain, as well as regulatory approvals for its products in various markets.

RUA Life Sciences Financial Statement Overview

Summary
RUA Life Sciences shows moderate revenue growth, but struggles with profitability and cash flow. The balance sheet is strong with low leverage, providing financial stability. However, persistent operating losses and negative cash flows are major concerns.
Income Statement
40
Negative
RUA Life Sciences has shown moderate revenue growth, with a 0.55% increase from 2023 to 2024. However, profitability remains a concern, as evidenced by persistent negative EBIT and net profit margins. Gross profit margins have improved to 78.33% for 2024, indicating cost management; however, the overall financial performance is weakened by substantial operating losses.
Balance Sheet
55
Neutral
The balance sheet shows a stable financial position with a strong equity base and low debt levels. The debt-to-equity ratio is low at 0.05, indicating minimal leverage. However, the company has not been able to turn equity into positive returns, as reflected by negative ROE. The equity ratio stands at 87.93%, demonstrating a solid equity position.
Cash Flow
45
Neutral
Cash flow analysis reveals challenges, with negative operating and free cash flows. The operating cash flow to net income ratio is less than optimal, highlighting cash flow issues. Free cash flow has improved slightly from the previous year but remains negative, indicating ongoing liquidity pressures.
BreakdownMar 2024Mar 2023Mar 2022Mar 2021Mar 2020
Income Statement
Total Revenue2.19M2.18M1.63M1.53M489.00K
Gross Profit1.72M1.43M1.04M980.00K489.00K
EBITDA-1.57M-1.95M-2.04M-1.28M-703.00K
Net Income-1.44M-2.00M-2.07M-1.45M-816.00K
Balance Sheet
Total Assets8.17M5.66M7.63M10.15M2.49M
Cash, Cash Equivalents and Short-Term Investments3.93M1.48M2.96M6.29M1.98M
Total Debt389.00K475.00K344.00K410.00K0.00
Total Liabilities987.00K864.00K868.00K1.65M219.00K
Stockholders Equity7.18M4.68M6.58M8.51M2.27M
Cash Flow
Free Cash Flow-1.38M-1.62M-3.27M-2.04M-436.00K
Operating Cash Flow-1.33M-1.17M-2.36M-1.42M-431.00K
Investing Cash Flow-85.00K-449.00K-904.00K-943.00K-5.00K
Financing Cash Flow3.89M132.00K-66.00K6.68M0.00

RUA Life Sciences Technical Analysis

Technical Analysis Sentiment
Negative
Last Price11.50
Price Trends
50DMA
11.98
Negative
100DMA
11.91
Negative
200DMA
12.02
Negative
Market Momentum
MACD
-0.12
Negative
RSI
34.17
Neutral
STOCH
58.06
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:RUA, the sentiment is Negative. The current price of 11.5 is below the 20-day moving average (MA) of 11.71, below the 50-day MA of 11.98, and below the 200-day MA of 12.02, indicating a bearish trend. The MACD of -0.12 indicates Negative momentum. The RSI at 34.17 is Neutral, neither overbought nor oversold. The STOCH value of 58.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:RUA.

RUA Life Sciences Peers Comparison

Overall Rating
UnderperformOutperform
Sector (57)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
67
Neutral
£25.29M-2.91%-5.33%60.20%
64
Neutral
£435.89M61.032.93%1.30%40.66%-55.09%
57
Neutral
£5.06B6.82-62.36%2.25%33.93%6.67%
55
Neutral
£7.14M1,150.000.08%56.29%
47
Neutral
$12.98M-83.56%238.31%63.09%
46
Neutral
£106.37M167.16%-100.00%-23.91%
37
Underperform
$24.84M425.97%-4.48%61.09%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:RUA
RUA Life Sciences
11.50
1.25
12.20%
GB:SCLP
Scancell Holdings
10.25
-5.55
-35.13%
GB:TRX
Tissue Regenix
35.50
-27.50
-43.65%
GB:AMS
Advanced Medical Solutions
202.00
-24.20
-10.70%
GB:POLX
Polarean Imaging
1.08
-0.60
-35.82%
GB:RENX
Renalytix
7.50
-6.00
-44.44%

RUA Life Sciences Corporate Events

M&A TransactionsBusiness Operations and StrategyFinancial Disclosures
RUA Life Sciences Reports Robust Revenue Growth and Strategic Expansion
Positive
Apr 24, 2025

RUA Life Sciences has reported significant revenue growth for the fiscal year ending March 31, 2025, with an 86% increase to £4.1 million, driven by strong underlying business performance and the acquisition of the Abiss Group. The company has successfully reduced costs and improved cash control, resulting in an expected EBITDA of £0.3 million, a turnaround from the previous year’s loss. The company is focusing on expanding its contract manufacturing business and exploring new opportunities with its unique IP, particularly in combining textiles expertise with Elast-Eon. The acquisition of Abiss is expected to be beneficial despite an initial period of reduced orders due to excess inventory. Structural changes in the market are anticipated to positively impact Abiss, and RUA is exploring new licensing opportunities for Elast-Eon in various therapeutic areas.

Spark’s Take on GB:RUA Stock

According to Spark, TipRanks’ AI Analyst, GB:RUA is a Neutral.

RUA Life Sciences faces significant operational challenges with negative profitability and cash flow, despite a strong balance sheet. Technical indicators suggest a bearish trend, while the high P/E ratio indicates potential overvaluation. However, positive corporate developments, such as the CEO’s confidence and subsidiary turnaround, offer some optimistic signals for future growth.

To see Spark’s full report on GB:RUA stock, click here.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 26, 2025